Brillia
For Children For Adults
Brillia Health
Cold-Flu Recovery Cough Control
Manufacturing
Quality control
Home - Manufacturing
Making Safe High-Quality Medicine

Santonika is a GMP-certified facility and operates high-quality, well-equipped manufacturing facilities located in Kaunas, Lithuania.

Our manufacture lines are equipped with well-known and renowned producers (Bosch, IMA, CAM, Ulhman, Marchesini) and allow us to focus on the production of the following dosage forms:

STERILE MEDICINE PRODUCTS
Ampoules and eye drops
SOLID MEDICINE PRODUCTS
Uncoated tablets and hard gelatine capsules
Santonika is

Devoted to the manufacture of its own pharmaceutical preparations as well as providing contract manufacture services to several of the world’s leading pharmaceutical companies.

Our advantage and strength rests in our ability to perform the entire product manufacture process
MANUFACTURING
PACKAGING
QUALITY CONTROL
RELEASE
The key of Santonika's success is its highly qualified, experienced and trained staff. Compliance with quality standards requires the employees to be committed and diligence with the goal of continuous improvement our qualifications.
Due to our internal training system, based on sharing the professional experience and skills from one employee to the other, Santonika's employees acquire specific professional knowledge which is not possible to receive in regular educational institutions.
Multicentre double-blind randomized placebo-controlled study “The Efficacy and Safety of Brillia for children in patients with attention deficit hyperactivity disorder (ADHD)”
Brillia for Сhildren significantly decreased the ADHD symptoms (by more than 50%) in 32% of patients with AHDH after 12 weeks of product use (assessed with ADHDRS-IV-Home Version scale)

*p<0.05 compared to placebo

#p<0.001 compared to baseline
Brillia for children has been found to improve attention by 31.7% after 12 weeks of product use (assessed with ADHDRS-IV-Home Version scale).

*p<0.01 compared to placebo
Brillia for children reduced ADHD symptoms severity by 36% after 12 weeks of product use (assessed with ADHDRS-IV-Home Version scale).
Multicentre double-blind randomized placebo-controlled study
“The efficacy and safety of Brillia for children
in patients with anxiety disorder”
Brillia for Children has been found to reduce anxiety symptoms up to 22% after 12 weeks of product use (assessed with the anxiety test of R. Temmpl, M. Dorki, V. Amen).